243 related articles for article (PubMed ID: 20019189)
1. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis.
Dongiovanni P; Fracanzani AL; Cairo G; Megazzini CP; Gatti S; Rametta R; Fargion S; Valenti L
Am J Pathol; 2010 Feb; 176(2):1006-17. PubMed ID: 20019189
[TBL] [Abstract][Full Text] [Related]
2. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
3. p53-independent induction of rat hepatic Mdm2 following administration of phenobarbital and pregnenolone 16alpha-carbonitrile.
Nelson DM; Bhaskaran V; Foster WR; Lehman-McKeeman LD
Toxicol Sci; 2006 Dec; 94(2):272-80. PubMed ID: 17000718
[TBL] [Abstract][Full Text] [Related]
4. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Zhang X; Zhang Z; Cheng J; Li M; Wang W; Xu W; Wang H; Zhang R
J Biol Chem; 2012 Aug; 287(36):30468-76. PubMed ID: 22787160
[TBL] [Abstract][Full Text] [Related]
6. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
8. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
9. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
10. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
11. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
[TBL] [Abstract][Full Text] [Related]
12. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
13. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
14. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus core protein overcomes H2O2-induced apoptosis by downregulating p14 expression via DNA methylation.
Seo YL; Heo S; Jang KL
J Gen Virol; 2015 Apr; 96(Pt 4):822-832. PubMed ID: 25535325
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
17. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
18. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner.
Zhu Z; Luo Z; Li Y; Ni C; Li H; Zhu M
Hepatology; 2009 Feb; 49(2):504-12. PubMed ID: 19085961
[TBL] [Abstract][Full Text] [Related]
19. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.
Li WF; Alfason L; Huang C; Tang Y; Qiu L; Miyagishi M; Wu SR; Kasim V
Acta Pharmacol Sin; 2023 Mar; 44(3):647-660. PubMed ID: 35995868
[TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
